Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a Locations section including Missouri (St. Louis, MO) for the study page and updated the revision to v3.3.3.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to study details or page layout are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedMinor software revision from v3.2.0 to v3.3.1; no changes to trial content or displayed information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedRemoved the government funding status notice. The study details on the page remain unchanged.SummaryDifference0.4%

- Check63 days agoChange DetectedCore study information remains the same between screenshots, including title, identifier (NCT04543279), status, eligibility criteria, interventions, and primary/secondary outcomes. Only minor layout or styling changes are visible.SummaryDifference0.4%

- Check92 days agoChange DetectedMajor update: new operating-status notice and v3.2.0 release; removal of v3.1.0.SummaryDifference3%

Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.